ORDER A TEST Log In Contact Us

ONCOLOGY /// GENOMIC PROFILING

One platform for precision oncology

At Tempus, we are changing the way precision oncology care is delivered. By leveraging clinical and molecular data, we offer comprehensive genomic profiling services, including hereditary testing, minimal residual disease and monitoring, and therapy selection, transforming the way cancer is diagnosed and treated.

Our single platform is a one-stop-shop for all your cancer testing needs, with a comprehensive portfolio and a vast multimodal database, we are making precision medicine a reality for patients everywhere.

Forging a new path in precision oncology

SOLID TUMOR + LIQUID BIOPSY

Maximize biomarker detection and identify more clinically actionable variants linked to targeted therapy options.

In a metastatic pan-cancer analysis of 1,448 patients with actionable variants, 9% of patients had unique actionable alterations found in liquid biopsy that were not detected in solid tumor alone.1,*

image description
The value of dual, solid tumor and liquid biopsy NGS testing
Read more

DNA SEQ + WHOLE TRANSCRIPTOME RNA SEQ

Enable a more complete understanding of clinically actionable fusions and altered splicing.

29% more patients, within a cohort of patients that had fusions discovered, were identified with a unique, clinically actionable fusion that matched to a targeted therapy with addition of RNA sequencing, compared to DNA sequencing alone.2,*

image description
The value of RNA sequencing
Read more

SOLID TUMOR + NORMAL MATCH

Provides accurate insight through true identification of somatic alterations and maximizes targeted therapy opportunities.

28% reduction in somatic false-positive calls, improving accuracy compared to a tumor-only analysis.3*

image description
The clinical benefits of tumor + normal match sequencing
Watch now

MINIMAL RESIDUAL DISEASE & MONITORING

Offering a portfolio of MRD and monitoring assays.

Finely tuned tumor-naive assay to help detect residual disease or recurrence in colorectal cancer.

Ultra sensitive assay to monitor residual disease and recurrence, as well as IO treatment response monitoring.

ROBUST AI CAPABILITIES

Expansive and developing portfolio of algorithmic testing capabilities and digital pathology platform leveraging ~7M de-identified research records.

Tempus One: the first step toward artificial intelligence enabled genomic reporting, to help you make data-driven precision medicine decisions.

image description
Tempus One
Read more

SINGLE PLATFORM SOMATIC + GERMLINE TESTING

Providing a comprehensive view of your patient’s molecular profile.

Identify patients with hereditary risk through streamlined cancer testing.

image description
The value of integrated clinical-molecular data
Read more

TAILORED TESTING SOLUTIONS

As part of our genomic sequencing portfolio, Tempus provides a comprehensive selection of tests to help empower you to customize treatment for your patients.

IHC tests:

  • PD-L1 Clones (22C3, 28-8, SP142, SP263)
  • MMR (MLH1, MSH2, MSH6, PMS2)
  • HER2†
    • Available for all solid tumor types, with reflex testing to ERBB2 FISH in cases of equivocal results (IHC score of 2+)‡
    • Additional analysis to support HER2 Ultra Low assessment for HER2 breast cancer orders with a score of 0.
  • FOLR1 (FRɑ)†
  • CLDN18†

Neuro-Oncology tests:

  • 1p/19q Co-Deletion†
  • MGMT Promoter Methylation†

Algorithmic tests:

  • Immune Profile Score (IPS)
  • Homologous Recombination Deficiency (HRD)
  • Tumor Origin (TO)
  • DPYD
  • UGT1A1
  • PurIST℠

†Powered by NeoGenomics

‡While FISH reflex will occur for equivocal IHC results in any solid tumor, it is currently only guideline-supported for select tumor types.4,5,6

Our comprehensive test offerings

  • xT CDx

FDA-Approved Tumor Profiling for Solid Tumor Malignancies

648 gene solid tumor + normal match DNA sequencing panel

—SNVs, MNVs, INDELs, MSI status, and CDx indications for CRC patients. Includes a professional services report for additional insights. Testing add-ons: IHC, FISH, and MGMT Promoter Methylation analysis

LEARN MORE Order
  • xR

Solid Tumor + Hematologic Malignancies

Whole-transcriptome RNA sequencing panel

—Testing add-ons: IHC, FISH, and MGMT Promoter Methylation analysis

LEARN MORE Order
  • xT

Solid Tumor Only or Hematologic Malignancies

648 gene DNA sequencing panel

LEARN MORE Order
  • xF
  • xF+

Liquid Biopsy

105/523 gene ctDNA sequencing panel

MSI-H status, bTMB

LEARN MORE Order
  • xG
  • xG+

+RNAinsight®

Hereditary Cancer Test (Powered by Ambry Genetics®)

39/76 gene panels for hereditary cancers

LEARN MORE Order
  • xE

Whole Exome

19,000+ gene DNA sequencing panel

TMB

—Testing add-ons: IHC analysis includes PD-L1 and MMR proteins

LEARN MORE Order
  • xM

Portfolio of MRD & Monitoring Assays

Tumor-naive and tumor-informed assays to detect residual disease or early cancer recurrence along with IO treatment response monitoring.

LEARN MORE Order

Algorithmic Tests

IPS, TO, HRD, DPYD, UGT1A1, PurIST℠, Merlin

LEARN MORE Order

Introducing xM, our new portfolio of MRD assays.

Learn more about xM

Tempus Smart Reporting

We are a leading profiling partner in the incorporation of MSK’s OncoKB™ and NCCN Guidelines®7 into clinical professional services reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.

Easy-to-Interpret Results

Actionable molecular findings.

https://www.tempus.com/wp-content/uploads/2024/04/Tempus-xT_Sample-ReportsBreast_results.jpg

Tempus Smart Reporting

We are a leading profiling partner in the incorporation of MSK’s OncoKB™ and NCCN Guidelines®7 into clinical professional services reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.

Therapy Options

Increased therapeutic options by leveraging OncoKB™ and NCCN Guidelines®.7

https://www.tempus.com/wp-content/uploads/2024/04/Tempus-xT_Sample-ReportsBreast_therapies.jpg

Tempus Smart Reporting

We are a leading profiling partner in the incorporation of MSK’s OncoKB™ and NCCN Guidelines®7 into clinical professional services reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.

THERAPY RESISTANCE

By combining clinical and molecular data, we provide you with insights into therapy resistance.

https://www.tempus.com/wp-content/uploads/2024/04/Tempus-xT_Sample-Reports-2.jpg

Tempus Smart Reporting

We are a leading profiling partner in the incorporation of MSK’s OncoKB™ and NCCN Guidelines®7 into clinical professional services reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.

CLINICAL TRIAL OPTIONS

96% of patients were potentially matched to a clinical trial when clinical data was combined with Tempus NGS.3,*

https://www.tempus.com/wp-content/uploads/2023/07/xT-Sample-ReportProstate_clinical-trial-options.jpg

Tempus Smart Reporting

We are a leading profiling partner in the incorporation of MSK’s OncoKB™ and NCCN Guidelines®7 into clinical professional services reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.

CLINICAL HISTORY

Patient’s clinical history captured within the report.

https://www.tempus.com/wp-content/uploads/2023/07/xT-Sample-ReportProstate_clinical-history.jpg

Ordering flexibility to help optimize your workflow

Tempus Hub

View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, derived from our vast library of molecular profiling data.

To access the Hub platform, visit hub.securetempus.com, and select the “Request Access” button.

Available on both desktop and mobile devices.

Learn more
image description

EHR Integration

Take advantage of Tempus’ rapidly growing multimodal dataset capabilities to structure, unify, and normalize your data for clinical trial matching, precision medicine analytics, publications, and AI development.

Learn more
image description

Mobile Phlebotomy

We want to make blood draw services as convenient as possible for your patients. For patients unable to visit a clinic, we can help to schedule a blood draw appointment at a location convenient to them.

To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.

image description
FINANCIAL ASSISTANCE

Tempus is committed to providing easy and affordable access to our tests and services.

  • Apply for financial assistance online at access.tempus.com.

  • If approved, you will know immediately about the maximum out of pocket cost of your testing.

  • Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

Authorization for Medical Records: Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.

Notice and Authorization for Medical Records

Tempus is working to make precision medicine a reality for cancer patients. Each person’s cancer and medical circumstances are unique. Tempus has a database of de-identified health information from many cancer patients. We believe we can improve cancer care and research, in the United States and abroad, by adding more de-identified health information to our database.

Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the Notice and Authorization for Medical Records form for more information.

Learn more

  1. Based on a retrospective study involving a cohort of randomly selected patients with breast, colorectal, lung, and prostate cancer. Iams, WT, MacKay M, Ben-Shachar R, et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open. 2024;7(1):e2351700-e2351700. Clinically actionable variants were identified using indication-matched recommendations from NCCN guidelines.
  2. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including low grade glioma, sarcoma, glioblastoma, bladder, NSCLC and biliary tract cancer, where a fusion was detected in 2.5% of samples overall (n=2,156/84,938). Michuda J, Park BH, Cummings AL, et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J Clin Oncol. 2022;40(16_suppl):3077.
  3. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including brain, breast, colorectal, lung, ovarian, endometrial, pancreatic and prostate cancer. Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37(11):1351-1360.
  4. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867-3872.
  5. Bartley AN, Washington MK, Ventura CB, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345-1363.
  6. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47-58.
  7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [1.2.25].

*This data is derived from the xT tumor + normal LDT assay.

xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/

This is data-driven precision medicine

This is the future of healthcare.